AI Article Synopsis
- CDT (Carbohydrate-deficient transferrin) is a biomarker used in Italy primarily to assess heavy alcohol consumption for driver’s license reissuance after offenses.
- In 2006, an increase in CDT testing was noted, with 142 laboratories performing these tests and 67 different license commissions using various protocols, indicating a significant rise from the previous year.
- There is a lack of standardization in testing methods, result expressions, and cut-off limits among the laboratories, highlighting an urgent need for uniform practices in CDT measurement.
Article Abstract
Background: Carbohydrate-deficient transferrin (CDT) in serum is a biomarker of heavy alcohol consumption. In Italy, CDT testing is primarily used for matters of road safety by the commissions that reissue drivers' licenses after alcohol-related offences. The purpose of this study was to examine how CDT determinations are carried out by Italian laboratories.
Methods: Public (hospital and university) laboratories, the companies producing CDT assays, and the organizers of two external quality assurance (EQA) programs were approached and telephone interviews were conducted. The study was carried out between October, 2006 and January, 2007, and considered the situation as of 31 December, 2006.
Results: In 2006, 142 Italian hospital and university laboratories performed CDT measurements and there were 67 license commissions using different protocols for the evaluation of alcohol abuse. Compared with 2005, the number of laboratories that assayed CDT had doubled in 2006. Several different CDT methods were in routine use and there were large differences in the ways results were expressed and in the cut-off limits applied, even for identical methods and instrumentations. Only approximately one-third of the laboratories participated in an EQA program for CDT.
Conclusions: Despite that CDT testing is used almost exclusively for medico-legal purposes in Italy, many different methods, ways of expressing test results, and cut-off limits were routinely applied. This observation points at the urgent need for standardization of CDT measurement.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1515/CCLM.2008.346 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Cricoid chondroma presenting as upper airway obstruction: A report of a rare case.
Radiol Case Rep
March 2025
Centre for Innovative Drug Development and Therapeutic Trials for Africa (CDT-Africa), College of Health Sciences, Addis Ababa University, Addis Ababa, Ethiopia.
Laryngeal chondroma is a very rare laryngeal tumor that commonly presents as dysphonia and dyspnea. A combination of clinical, histological, and radiological data has paramount importance for accurate diagnosis of this rare disease. It is difficult to differentiate laryngeal chondroma from chondrosarcoma solely based on radiological imaging; therefore, radiologists need to specify the origin of the tumor and the level of extension.
View Article and Find Full Text PDFTailored biomimetic nanoreactor improves glioma chemodynamic treatment via triple glutathione depletion and prompt acidity elevation.
Mater Today Bio
February 2025
Department of Neurosurgery, Research Center of Clinical Medicine, Affiliated Hospital of Nantong University, Nantong University, Nantong, 226001, China.
Chemodynamic therapy (CDT) is an emerging antitumor strategy utilizing iron-initiated Fenton reaction to destroy tumor cells by converting endogenous HO into highly toxic hydroxyl radical (OH). However, the intratumoral overexpressed glutathione (GSH) and deficient acid greatly reduce CDT efficacy because of OH scavenging and decreased OH production efficiency. Even worse, the various physiological barriers, especially in glioma, further put the brakes on the targeted delivery of Fenton agents.
View Article and Find Full Text PDFCarbon-supported Fe single atom nanozymes with long-lasting ROS generation and high NIR photothermal performance for synergistic cancer therapy.
J Colloid Interface Sci
April 2025
High Magnetic Field Laboratory, Hefei Institutes of Physical Science, Chinese Academy of Science, Hefei, Anhui 230031, PR China; University of Science and Technology of China, Hefei, Anhui 230026, PR China. Electronic address:
Synergistic therapy combining photothermal therapy (PTT) and chemodynamic therapy (CDT) has proven to be a highly effective strategy for cancer treatment. However, PTT heavily relies on the accumulation of therapeutic agents at the tumor site. The peroxidase (POD) activity of common catalysts can be rapidly exhausted during the accumulation process, prior to laser intervention, thereby diminishing the synergistic enhancement effect of the combined therapy.
View Article and Find Full Text PDFHyaluronic acid modified metal-organic frameworks loading cisplatin achieve combined chemodynamic therapy and chemotherapy for lung cancer.
Int J Biol Macromol
January 2025
Department of Oncology, the Affiliated Hospital of Southwest Medical University, Luzhou, Sichuan 646000, PR China; Nuclear Medicine and Molecular Imaging Key Laboratory of Sichuan Province, Luzhou, Sichuan 646000, PR China. Electronic address:
As one of the most commonly used chemotherapeutic agents in clinical practice, cisplatin is unable to selectively accumulate in tumor tissue due to its lack of targeting ability, leading to increased systemic toxicities. Additionally, the effectiveness of monotherapy is greatly limited. Therefore, the development of new cisplatin-based drug delivery systems is essential to improve the effectiveness of tumor treatment.
View Article and Find Full Text PDFNear-infrared-triggered release of self-accelerating cascade nanoreactor delivered by macrophages for synergistic tumor photothermal therapy/starvation therapy/chemodynamic therapy.
J Colloid Interface Sci
January 2025
State Key Laboratory of Medicinal Chemical Biology, Tianjin Key Laboratory of Biosensing and Molecular Recognition, Research Center for Analytical Sciences, College of Chemistry, Nankai University, Tianjin 300071 China; National Chromatographic Research and Analysis Center, Dalian Institute of Chemical Physics, Chinese Academy of Sciences, Dalian 116023 China.
Macrophages have emerged as promising cellular vehicles for the delivery of therapeutic agents to tumor sites. However, the cytotoxicity of therapeutic agents toward the cellular carriers and the effective release of therapeutic agents at the tumor site remain the main challenges faced by macrophage-mediated drug delivery systems. Herein, a near-infrared (NIR)-triggered release of self-accelerating cascade nanoreactor (HCFG) delivered by macrophages (HCFG@R) was developed for synergistic tumor photothermal therapy (PTT)/starvation therapy (ST)/chemodynamic therapy (CDT).
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!